Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations

Affiliations

• ¹ Centro Studi Sclerosi Multipla, Ospedale di Gallarate, ASST Valleolona, Gallarate, Italy.
• ² Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
• ³ Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA/Center for Neuroinflammation and Experimental Therapeutics and the Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
• ⁴ Partners Pediatric MS Center, Massachusetts General Hospital, Boston, MA, USA.
• ⁵ Kids Neuroscience Centre and Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
• ⁶ Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
• ⁷ Department of Neurology, Medical University of Vienna, Vienna, Austria.
• ⁸ Multiple Sclerosis Comprehensive Care Center, Department of Neurology, NYU Langone Health, New York, NY, USA.
• ⁹ UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
• ¹⁰ Pediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.
• ¹¹ Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Witten, Germany.
• ¹² Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
• ¹³ Children's Hospital Colorado, University of Colorado, Aurora, CO, USA.
• ¹⁴ Pediatric Neuroimmunology Program, Department of Neurology, National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina.
• ¹⁵ UCSF Pediatric MS Clinic and UCSF Adult MS Clinic, Department of Neurology, University of California at San Francisco, San Francisco CA, USA.